Literature DB >> 32516855

An assessment of the role of vinculin loss of function variants in inherited cardiomyopathy.

Megan H Hawley1, Naif Almontashiri2, Leslie G Biesecker3, Natalie Berger4, Wendy K Chung5, John Garcia6, Theresa A Grebe7, Melissa A Kelly8, Matthew S Lebo1, Daniela Macaya9, Hui Mei9, Julia Platt10, Gabi Richard9, Ashley Ryan7, Kate L Thomson11, Matteo Vatta6, Roddy Walsh12, James S Ware13,14, Matthew Wheeler10, Hana Zouk1, Heather Mason-Suares1, Birgit Funke1.   

Abstract

The ACMG/AMP variant classification framework was intended for highly penetrant Mendelian conditions. While it is appreciated that clinically relevant variants exhibit a wide spectrum of penetrance, accurately assessing and expressing the pathogenicity of variants with lower penetrance can be challenging. The vinculin (VCL) gene illustrates these challenges. Model organism data provide evidence that loss of function of VCL may play a role in cardiomyopathy and aggregate case-control studies suggest low penetrance. VCL loss of function variants, however, are rarely identified in affected probands and therefore there is a paucity of family studies clarifying the clinical significance of individual variants. This study, which aggregated data from >18,000 individuals who underwent gene panel or exome testing for inherited cardiomyopathies, identified 32 probands with VCL loss-of-function variants and confirmed enrichment in probands with dilated cardiomyopathy (odds ratio [OR] = 9.01; confidence interval [CI] = 4.93-16.45). Our data revealed that the majority of these individuals (89.5%) had pediatric onset of disease. Family studies demonstrated that heterozygous loss of function of VCL alone is insufficient to cause cardiomyopathy but that these variants do contribute to disease risk. In conclusion, VCL loss-of-function variants should be reported in a diagnostic setting but need to be clearly distinguished as having lower penetrance.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  VCL; cardiomyopathy gene panel testing; dilated cardiomyopathy; dilated cardiomyopathy genetics; pediatric cardiomyopathy; risk allele; vinculin; vinculin loss of function

Mesh:

Substances:

Year:  2020        PMID: 32516855      PMCID: PMC7714388          DOI: 10.1002/humu.24061

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.700


  41 in total

1.  Metavinculin mutations alter actin interaction in dilated cardiomyopathy.

Authors:  Timothy M Olson; Susanne Illenberger; Nina Y Kishimoto; Stefan Huttelmaier; Mark T Keating; Brigitte M Jockusch
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy.

Authors:  Irene Bottillo; Daniela D'Angelantonio; Viviana Caputo; Alessandro Paiardini; Martina Lipari; Carmelilia De Bernardo; Diana Giannarelli; Antonio Pizzuti; Silvia Majore; Marco Castori; Elisabetta Zachara; Federica Re; Paola Grammatico
Journal:  Gene       Date:  2015-12-02       Impact factor: 3.688

3.  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion.

Authors:  Ahmad N Abou Tayoun; Tina Pesaran; Marina T DiStefano; Andrea Oza; Heidi L Rehm; Leslie G Biesecker; Steven M Harrison
Journal:  Hum Mutat       Date:  2018-09-07       Impact factor: 4.878

4.  Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.

Authors:  Pascale Richard; Philippe Charron; Lucie Carrier; Céline Ledeuil; Theary Cheav; Claire Pichereau; Abdelaziz Benaiche; Richard Isnard; Olivier Dubourg; Marc Burban; Jean-Pierre Gueffet; Alain Millaire; Michel Desnos; Ketty Schwartz; Bernard Hainque; Michel Komajda
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

5.  Multiple Gene Variants in Hypertrophic Cardiomyopathy in the Era of Next-Generation Sequencing.

Authors:  Charlotte Burns; Richard D Bagnall; Lien Lam; Christopher Semsarian; Jodie Ingles
Journal:  Circ Cardiovasc Genet       Date:  2017-08

6.  Vinculin b deficiency causes epicardial hyperplasia and coronary vessel disorganization in zebrafish.

Authors:  Feng Cheng; Liyun Miao; Qing Wu; Xia Gong; Jingwei Xiong; Jian Zhang
Journal:  Development       Date:  2016-08-30       Impact factor: 6.868

7.  Vinculin knockout results in heart and brain defects during embryonic development.

Authors:  W Xu; H Baribault; E D Adamson
Journal:  Development       Date:  1998-01       Impact factor: 6.868

8.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

9.  Investigation of Pathogenic Genes in Chinese sporadic Hypertrophic Cardiomyopathy Patients by Whole Exome Sequencing.

Authors:  Jing Xu; Zhongshan Li; Xianguo Ren; Ming Dong; Jinxin Li; Xingjuan Shi; Yu Zhang; Wei Xie; Zhongsheng Sun; Xiangdong Liu; Qiming Dai
Journal:  Sci Rep       Date:  2015-11-17       Impact factor: 4.379

10.  Molecular analysis of inherited cardiomyopathy using next generation semiconductor sequencing technologies.

Authors:  Chaoxia Lu; Wei Wu; Fang Liu; Kunqi Yang; Jiacheng Li; Yaping Liu; Rongrong Wang; Nuo Si; Peng Gao; Yongtai Liu; Shuyang Zhang; Xue Zhang
Journal:  J Transl Med       Date:  2018-08-30       Impact factor: 5.531

View more
  1 in total

Review 1.  Understanding the molecular basis of cardiomyopathy.

Authors:  Marie-Louise Bang; Julius Bogomolovas; Ju Chen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-11-19       Impact factor: 5.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.